News

Article

BioNTech and Roche Publish Personalized Vaccine Data

Author(s):

The data, published in the scientific journal Nature, demonstrated that half of patients developed T cells that could potentially fight pancreatic ductal adenocarcinoma.

Data from a Phase I clinical trial of BioNTech and Roche’s personalized cancer vaccine candidate, adjuvant autogene cevumeran, was published in Nature on May 10, 2023. The study evaluated the vaccine’s ability to fight pancreatic ductal adenocarcinoma (PDAC), an aggressive form of pancreatic cancer that the study noted is the third leading cause of death from cancer in the United States and lethal in approximately 88% of patients.

The treatment is an individualized neoantigen vaccine based on uridine messenger RNA (mRNA)–lipoplex nanoparticles, which was developed using mRNA neoantigen vaccines in real time from surgically resected PDAC tumors. When treated with adjuvant autogene cevumeran, in combination with atezolizumab and mFOLFIRINOX, eight of the 16 patients developed T cells that could potentially fight PDAC. Vaccine-expanded T cells were durable, persisting up to two years after injection.

“High-magnitude vaccine-induced T-cell responses, the focus of our immune response analysis that included a new method to track vaccine-expanded clones, correlated with delayed PDAC recurrence,” reads the study. “Despite the limited sample size, these early results warrant larger studies of individualized mRNA neoantigen vaccines in PDAC.”

Source: Nature

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content